Slideshow
Top 5 bladder cancer articles of 2019
The BCG shortage, overuse of cystoscopy, and hematuria evaluation approaches are among the topics of the most-read Urology Times articles from 2019 on bladder cancer.
Sense of urgency surrounds BCG shortage
As urologists maneuver through the third shortage of bacillus Calmette-Guérin during the past decade, there is a sense of urgency to find short- and long-term alternative treatments to the only FDA-approved BCG strain as a therapeutic agent for nonmuscle-invasive bladder cancer.
Read the article here
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Can ctDNA detect molecular residual disease in NMIBC?
Betty Wang, MD, and Laura Bukavina, MD, MPH, MSc, discuss ctDNA's role in NMIBC treatment decisions
TMT for bladder cancer: Balancing cost and quality of life
Anne Schuckman, MD, outlines current challenges in NMIBC care
Investigators compare trimodal therapy vs cystectomy in MIBC
Investigators assess ctDNA’s role in NMIBC
RX Review: Implementing mitomycin for LG-IR-NMIBC in clinical practice
RX Review: TURBT vs chemoablation for low-grade, intermediate-risk NMIBC
RX Review: A paradigm shift for low-grade, intermediate-risk NMIBC
RX Review: How mitomycin for intravesical solution works in treating LG-IR-NMIBC
Related Content
